Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 4Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Neoplasm, Residual 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

pembrolizumab 111Carboplatin 45Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 27Specimen Handling 25venetoclax 24Magnetic Resonance Spectroscopy 24Pemetrexed 23fludarabine 22Biopsy 22Radiotherapy 21Ipilimumab 21Docetaxel 21Bevacizumab 21Azacitidine 21Radiosurgery 18durvalumab 17Fluorouracil 17Dexamethasone 17Cetuximab 16fludarabine phosphate 14Trastuzumab 14Leucovorin 13Cytarabine 13tislelizumab 12olaparib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × sabatolimab × 1 year × Clear all
NCT04150029 2026-01-13

STIMULUS-AML1

Novartis

Phase 2 Terminated
90 enrolled 26 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04266301 2026-01-13

STIMULUS-MDS2

Novartis

Phase 3 Terminated
530 enrolled 29 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04623216 2025-10-16

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Novartis

Phase 1/2 Terminated
24 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03940352 2025-10-10

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Novartis

Phase 1 Terminated
52 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡